�Cytokinetics, Incorporated (NASDAQ: CYTK) announced that data from an on-going Phase I/II clinical trial of ispinesib are scheduled to be presented as a bill poster presentation at the 2008 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium, to be held September lvii, 2008 at the Hilton Washington in Washington, DC.
In June 2008, as part of a notice session at the ASCO Annual Meeting, Cytokinetics proclaimed interim data from the Phase I portion of its on-going Phase I/II clinical trial of ispinesib, a novel kinesin mandril protein (KSP) inhibitor, administered as monotherapy as a first-line treatment in chemotherapy-na�ve patients with locally advanced or metastatic breast genus Cancer. The authors concluded that preliminary data suggest that ispinesib is well-tolerated when dosed on days 1 and 15 every 28 days at doses up to 12 mg/m2. Results from extra patients enrolled in the ongoing Phase I, dose-escalation portion of this clinical trial are scheduled to be presented the 2008 ASCO Breast Cancer Symposium.
Poster Presentation at ASCO Breast Cancer Symposium
Abstract #192: "A Phase I-II Trial of Ispinesib, a Kinesin Spindle Protein (KSP) Inhibitor, Dosed Every Two Weeks in Patients (pts) with Locally Advanced (LA) or Metastatic Breast Cancer (MBC) Previously Untreated with Chemotherapy (CT) for Metastatic Disease or Recurrence." (Poster Presentation on Friday, September 5, 2008, during the General Poster Session, 5:30 pm - 6:45 pm Eastern Time). The poster will be ground in the Exhibit Hall at posting board #A50 and presented by Henry Gomez, MD from Instituto Nacional de Enfermedades Neoplasicas (INEN) in Lima, Peru.
About Cytokinetics
Cytokinetics is a biopharmaceutical company focused on the discovery, development and commercialisation of novel small molecule drugs that may call areas of significant unmet clinical necessarily. Cytokinetics' cardiovascular disease broadcast is focused to cardiac myosin, a motor protein essential to cardiac brawniness contraction. Cytokinetics' lead heighten from this program, CK-1827452, a novel small molecule cardiac myosin activator, entered Phase II clinical trials for the treatment of heart failure in 2007. Under a strategic alliance established in 2006, Cytokinetics and Amgen Inc. ar performing joint research focused on identifying and characterizing activators of cardiac myosin as backup and follow-on potential dose candidates to CK-1827452. Amgen has obtained an pick for an exclusive permit to develop and commercialize CK-1827452, content to Cytokinetics' development and commercial participation rights. Cytokinetics' cancer programme is focussed on mitotic kinesins, a family of motor proteins essential to cell division. Under a strategic alignment established in 2001, Cytokinetics and GlaxoSmithKline (GSK) ar conducting research and development activities focused on the potential handling of cancer. Cytokinetics is developing deuce novel drug candidates that have arisen from this program, ispinesib and SB-743921, each a novel inhibitor of kinesin spindle protein (KSP), a mitotic kinesin. Cytokinetics is sponsoring a Phase I/II clinical trial of ispinesib as monotherapy as a first-line treatment in chemotherapy-na�ve patients with locally advanced or metastatic breast malignant neoplastic disease. In addition, Cytokinetics is conducting a Phase I/II trial of SB-743921 in patients with non-Hodgkin or Hodgkin lymphomas. GSK has obtained an option for the reefer development and commercialization of ispinesib and SB-743921. Cytokinetics and GSK are conducting collaborative research activities directed to the mitotic kinesin centromere-associated protein E (CENP-E). GSK-923295, a CENP-E inhibitor, is being developed under the strategical alliance by GSK; GSK began a Phase I clinical trial run with GSK-923295 in 2007. In April 2008, Cytokinetics announced the selection of a potential drug nominee directed towards skeletal brawniness contractility which may be developed as a electric potential treatment for skeletal muscular tissue weakness associated with neuromuscular diseases or other atmospheric condition. All of these drug candidates and potential do drugs candidates experience arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a building complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at hTTP://www.cytokinetics.com.
This press button contains modern statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any purport or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, just are not limited to, statements relating to Cytokinetics' research and development programs, including planned presentations relating to clinical trial results, and the properties and potential benefits of Cytokinetics' drug candidates and potential difference drug candidates. Such statements are based on management's current expectations, but existent results may differ materially due to various risks and uncertainties, including, simply not modified to, electric potential difficulties or delays in the development, testing, regulative approval or production of Cytokinetics' dose candidates that could ho-hum or forbid clinical growth or product approval, including risks that current and past results of clinical trials or preclinical studies may non be indicatory of future clinical trials results, patient enrollment for clinical trials may be difficult or delayed, Cytokinetics' drug candidates may possess adverse side effects or inadequate remedial efficacy, the U.S. Food and Drug Administration or foreign regulatory agencies may delay or limit Cytokinetics' or its partners' power to conduct clinical trials, and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual attribute; Cytokinetics may incur out of the blue research and development and other costs or be unable to obtain additional financing necessary to lead development of its products; standards of care may change and others may introduce products or substitute therapies for the treatment of indications Cytokinetics' dose candidates and potential dose candidates may target; and risks and uncertainties relating to the timing and receipt of payments from Cytokinetics' partners, including milestones and royalties on future potential product sales under its quislingism agreements with such partners. For further information regarding these and other risks related to Cytokinetics' commercial enterprise, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.
Cytokinetics
More info
Subscribe to:
Posts (Atom)